In line with the controversial BNIP3 role, we would like to highlight the need for any future systemic translational approaches (e.g., pharmacological) aimed at targeting BNIP3 in experimental cancer models or patients to carefully consider the potential effects and outcomes on all tissues, whether normal or tumoral. The gene discussed is BNIP3; the disease is cancer.